Pancreatic Neuroendocrine Tumors Explained From Diagnosis to Treatment

Pancreatic neuroendocrine tumors represent a heterogeneous and increasingly diagnosed group of malignancies that differ substantially from the more common pancreatic adenocarcinoma. Their rising incidence, partly attributable to improved imaging detection, makes understanding their biology and management increasingly relevant to clinicians and patients alike.

These tumors originate from the endocrine islet cells of the pancreas and can occur sporadically or in the setting of hereditary syndromes including MEN1, von Hippel-Lindau disease, neurofibromatosis type 1, and tuberous sclerosis complex. Tumorigenesis is driven by mutations in MEN1, DAXX, ATRX, and components of the mTOR signaling pathway, which collectively promote uncontrolled cellular proliferation.

Clinically, pNETs are divided into functional tumors — which secrete active hormones producing recognizable syndromes such as hypoglycemia in insulinoma — and nonfunctional tumors, which often remain silent until they cause mass effect or metastasize, most frequently to the liver and lymph nodes. Diagnosis involves measuring chromogranin A and relevant serum hormones, paired with cross-sectional imaging and gallium-68 DOTATATE PET/CT for functional localization.

Management depends heavily on stage and grade. Surgical resection remains the cornerstone for localized disease, ranging from enucleation of small lesions to formal pancreatectomy. For advanced or inoperable disease, treatment options have expanded to include somatostatin analogs, mTOR inhibitor everolimus, tyrosine kinase inhibitor sunitinib, peptide receptor radionuclide therapy, and cytotoxic chemotherapy.

Prognosis varies dramatically by grade and stage. Well-differentiated, low-grade localized tumors carry five-year survival rates approaching 90%, while poorly differentiated or metastatic disease carries substantially worse outcomes. This review underscores the importance of early detection, accurate grading, and individualized multimodal treatment strategies.